Weekly Analysts’ Ratings Updates for Natera (NTRA)

A number of firms have modified their ratings and price targets on shares of Natera (NASDAQ: NTRA) recently:

• 8/10/2026 – Natera had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $355.00 price target on the stock.
• 8/7/2026 – Natera had its price target raised by TD Cowen from $325.00 to $340.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Natera had its price target raised by Royal Bank Of Canada from $275.00 to $350.00. They now have an “outperform” rating on the stock.
• 8/7/2026 – Natera was given a new $348.00 price target by Robert W. Baird.
• 8/7/2026 – Natera was given a new $375.00 price target by Canaccord Genuity Group Inc..
• 8/7/2026 – Natera had its price target raised by Wells Fargo & Company from $220.00 to $284.00. They now have an “equal weight” rating on the stock.
• 8/7/2026 – Natera had its price target raised by Citigroup Inc. from $300.00 to $315.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Natera had its price target raised by BTIG Research from $290.00 to $320.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Natera was given a new $330.00 price target by Leerink Partners.
• 8/7/2026 – Natera had its “overweight” rating reaffirmed by Barclays PLC. They now have a $340.00 price target on the stock.
• 8/7/2026 – Natera had its price target raised by JPMorgan Chase & Co. from $315.00 to $360.00. They now have an “overweight” rating on the stock.
• 7/17/2026 – Natera had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/15/2026 – Natera had its “buy” rating reaffirmed by TD Cowen.
• 7/14/2026 – Natera was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/14/2026 – Natera had its price target raised by Canaccord Genuity Group Inc. from $285.00 to $330.00. They now have a “buy” rating on the stock.
• 7/9/2026 – Natera had its price target raised by Morgan Stanley from $250.00 to $310.00. They now have an “overweight” rating on the stock.
• 7/6/2026 – Natera had its “outperform” rating reaffirmed by Evercore Inc. They now have a $300.00 price target on the stock.
• 6/29/2026 – Natera had its price target raised by Guggenheim from $270.00 to $290.00. They now have a “buy” rating on the stock.
• 6/26/2026 – Natera is now covered by Sanford C. Bernstein. They set an “outperform” rating and a $310.00 price target on the stock.
• 6/25/2026 – Natera was upgraded by Sanford C. Bernstein to “strong-buy”.
• 6/24/2026 – Natera was given a new $275.00 price target by BTIG Research. They now have a “buy” rating on the stock.
• 6/24/2026 – Natera was given a new $260.00 price target by UBS Group AG.
• 6/24/2026 – Natera had its price target lowered by Barclays PLC from $280.00 to $260.00. They now have an “overweight” rating on the stock.
• 6/23/2026 – Natera had its price target raised by BTIG Research from $250.00 to $270.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In related news, CFO Michael Burkes Brophy sold 478 shares of the business’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $274.22, for a total value of $131,077.16. Following the completion of the sale, the chief financial officer owned 51,637 shares of the company’s stock, valued at approximately $14,159,898.14. The trade was a 0.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,410 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80. Following the transaction, the insider owned 129,019 shares of the company’s stock, valued at $34,264,866.02. This represents a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 181,045 shares of company stock valued at $41,330,968 over the last ninety days. 5.05% of the stock is owned by corporate insiders.

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.